Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F12%3A11443" target="_blank" >RIV/00216208:11110/12:11443 - isvavai.cz</a>

Alternative codes found

RIV/00843989:_____/12:00103090 RIV/00064203:_____/12:8574 RIV/00064165:_____/12:11443

Result on the web

<a href="http://dx.doi.org/10.1016/S1474-4422(12)70056-X" target="_blank" >http://dx.doi.org/10.1016/S1474-4422(12)70056-X</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

Original language description

Background Fingolimod 0.5 mg once daily is approved for treatment of relapsing multiple sclerosis (MS). In the phase 3, 2-year FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in MS) study, fingolimod significantly reduced annualised relapse rates (ARRs) and the risk of confirmed disability progression compared with placebo. We aimed to investigate whether the beneficial treatment effect reported for the overall population is consistent in subgroups of patients with different baselinecharacteristics. Findings Treatment with fingolimod 0.5 mg was associated with significantly lower ARRs versus placebo across all subgroups except for patients aged over 40 years. ARR ratios ranged from 0.76 (95% CI 0.54-1.09; p=0.13) in patients aged over 40 years to 0.29 (0.16-0.52; p<0.0001) in patients who had relapse activity despite receiving interferon beta during the year before study enrolment. Hazard ratios for confirmed disability progression over 24 months with fingolimod 0.5

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FH - Neurology, neuro-surgery, nuero-sciences

OECD FORD branch

—

Project

—

Continuities

Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Lancet Neurology

ISSN

1474-4422

e-ISSN

—

Volume of the periodical

11

Issue of the periodical within the volume

5

Country of publishing house

GB - UNITED KINGDOM

Number of pages

9

Pages from-to

420-428

UT code for WoS article

000303138300013

EID of the result in the Scopus database

—